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A novel series of tubulin polymerization inhibitors, based on the 1-(3′,4′,5′-trimethoxyphenyl)-2-aryl-
1H-imidazole scaffold and designed as cis-restricted combretastatin A-4 analogues, was synthesized 
with the goal of evaluating the effects of various patterns of substitution on the phenyl at the 2-position 
of the imidazole ring on biological activity. A chloro and ethoxy group at the meta- and para-positions, 
respectively, produced the most active compound in the series (4o), with IC50 values of 0.4-3.8 nM 
against a panel of seven cancer cell lines. Except in HL-60 cells, 4o had greater antiproliferative than 
CA-4, indicating that the 3′-chloro-4′-ethoxyphenyl moiety was a good surrogate for the CA-4 B-ring. 
Experiments carried out in a mouse syngenic model demonstrated high antitumor activity of 4o, which 
significantly reduced the tumor mass at a dose thirty times lower than that required for CA-4P, which 
was used as a reference compound. Altogether, our findings suggest that 4o is a promising anticancer 
drug candidate that warrants further preclinical evaluation.
The microtubule system of eukaryotic cells is essential in a variety of fundamental cellular processes, including 
mitosis, formation and maintenance of cell shape, regulation of motility, cell signalling, secretion and intracellular 
transport1. Among the various strategies developed to block mitosis, the design of molecules that bind to tubulin 
and inhibit the formation of the mitotic spindle remains important for the development of anticancer agents2. 
Combretastatin A-4 (CA-4, 1a, Fig. 1), isolated from the bark of the South African tree Combretum caffrum3, is 
one of the well-known natural molecules that strongly inhibits tubulin polymerization by binding to the colchi-
cine site, and 1a arrests cells in mitosis in nanomolar concentrations4. CA-4 shows potent cytotoxicity against a 
wide variety of human cancer cell lines at low to mid nanomolar concentrations, including those that are multi-
drug resistant5. The vascular disrupting properties of CA-4 and related compounds represent a new approach for 
cancer treatment6. The water-soluble disodium phosphate prodrug of CA-4 (named CA-4P, 1b) has shown prom-
ising results in phase II and III clinical trials on advanced cancer based on the vascular shutdown mechanism of 
action7, thus stimulating significant interest in a variety of CA-4 analogues8.
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Because of its activity and structural simplicity, a wide number of CA-4 analogues have been synthesized 
with modifications to ring A, ring B and the bridge8. Previous structure-activity relationship (SAR) studies have 
demonstrated that both the 3′ ,4′ ,5′ -trimethoxy substitution pattern on the A-ring and the cis-olefin configuration 
at the bridge were fundamental requirements for optimal activity, while some B-ring structural modifications were 
tolerated by the target8,9. Structural modifications on the B-ring suggest that the 4′ -methoxy group is crucial for 
cytotoxicity, while the 3′ -hydroxy moiety is not necessary for potent activity9. However, the cis-configuration of 
CA-4 is prone to isomerize to the thermodynamically more stable trans-form during storage and in the course of 
metabolism in liver microsomes, resulting in a dramatic decrease in antitumor activity, although the two isomers 
have showed a similar uptake and disposition inside the cells10. Thus, to retain the appropriate spatial arrangement 
of the two adjacent aryl groups required for potent bioactivity, chemically stable cis-restricted derivatives of CA-4 
with general structure 2 were obtained by incorporating the olefinic double bond with vicinal diaryl-substituted 
five-member aromatic heterocyclic rings, such as pyrazole11, imidazole11,12, thiazole13, furazan (1,2,5-oxadiazole)14 
isoxazole15, oxazole11, 1,2,3-thiadiazole16, isomeric triazole17, tetrazole18, furan19 and thiophene19.
In a previous study, Wang and co-workers reported the preparation of 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-(4′ 
-N,N-dimethylaminophenyl)-1H-imidazole 3a, with antiproliferative activity inferior to that of CA-4 against 
HCT-15 (human colon adenocarcinoma) and NCI-H460 (human lung large cell carcinoma) cancer cell lines, 
with IC50 values of 80 and 270 nM, respectively11. Moreover, this compound had activity considerably reduced 
(IC50 = 35 μ M) relative to the activity of CA-4 as an inhibitor of tubulin polymerization.
Among a small series of 1,2-diaryl-1H-imidazoles synthesized by Bellina et al.12, the 1-(3′ ,4′ ,5′ 
-trimethoxyphenyl)-2-substituted-1H-imidazole derivatives 3b and 3c showed different antiproliferative activity 
against the HCT-15 and NCI-H460 cell lines. The 4′ -methoxyphenyl derivative 3b showed moderate antiprolif-
erative activity, with IC50 values of 1.1 and 1.6 μ M against NCI-H460 and HCT-15 cells, respectively, while the 
2′ -naphthyl derivative 3c had antiproliferative activity significantly higher than that of 3b, with IC50 values of 57 
Figure 1. Lead structures of tubulin polymerization inhibitors. 
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and 51 nM, respectively. Compounds 3a–c were regioselectively prepared by the direct C-2 arylation of 1-(3′ ,4′ , 
5′ -trimethoxy)-1H-imidazole with the required aryl iodide. However this methodology was characterized from 
several limitations: a) high temperatures and long reaction times; b) the use of twice the stoichiometric amount of 
copper iodide; c) tedious chromatographic separations; and d) limited commercially available substrate.
In our efforts to discover new potent antimitotic agents in which the cis-olefinic bridge of CA-4 was replaced 
by the polar and ionizable imidazole ring, we developed an efficient and versatile convergent synthetic procedure 
for the preparation of a new series of 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-aryl-1H-imidazoles with general struc-
ture 4, prepared starting with a 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-bromo-1H-imidazole intermediate. Because it is 
well-known that the trimethoxyphenyl skeleton can be essential for maximal tubulin binding activity, all newly 
prepared compounds maintained one of the aryl groups as a 3′ ,4′ ,5′ -trimethoxyphenyl moiety, identical with the 
A-ring of CA-4. Thus, once the 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-1H-imidazole motif was identified as the minimum 
structural requirement for activity, modifications that would further enhance the activity of previously published 
compounds 3a–c were focused on varying the other aryl moiety at the 2-position of the imidazole skeleton. This 
ring corresponds to the B-ring of CA-4, and we replaceed the methoxy group at the para-position of the phenyl 
ring of compound 3b with various electron-releasing (Me, Et, EtO, n-PrO, MeS, EtS) groups. The methoxy and 
ethoxy groups proved to be favorable for bioactivity, and, in the attempt to further increase antiproliferative 
activity, we introduced additional substituents (F, Cl, Me and MeO) at the meta-position of the para-methoxy/
ethoxyphenyl ring.
Chemistry
The synthetic protocol employed for the preparation of 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-aryl-1H-imidazoles 
with general structure 4 is shown in Fig. 2. The 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-1H-imidazole 5 was obtained by 
a Ullmann-type direct N-arylation procedure of 1H-imidazole with 1-bromo-3,4,5-trimethoxybenzene in the 
presence of Cs2CO3 and a catalytic amount of CuI20. The regioselective electrophilic bromination at the C-2 
Figure 2. General synthetic procedure followed for the preparation of compounds 4a–q. Reagents. (a) 
1-bromo-3,4,5-trimethoxybenzene, Cs2CO3, CuI, DMF, 120 °C, 40 h; (b) NBS, CH3CN, rx; (c) PdCl2(DPPF), 
ArB(OH)2, CsF, 1,4-dioxane, 65 °C.
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position of compound 5 with N-bromosuccinimide (NBS) in refluxing acetonitrile led to the formation of the 
key intermediate 6, which was subjected to Suzuki cross-coupling conditions in the presence of the appropriate 
arylboronic acid under heterogeneous conditions [PdCl2(DPPF), CsF] in 1,4-dioxane at 65 °C, to furnish final 
compounds 4a–q.
Biological Results and Discussion
In vitro antiproliferative activities.  The 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-aryl-1H imidazoles 4a–q were 
evaluated for their antiproliferative activity against a panel of seven human tumor cell lines and compared with 
the known 4′ -methoxyphenyl and 2′ -naphthyl imidazole analogues 3b and 3c, respectively, as well as CA-4 (1a) 
as reference compounds. The data shown in Table 1 indicated the importance of substituents on the phenyl ring 
at the 2-position of the imidazole system for activity and selectivity against different cancer cell lines. Three of 
the synthesized compounds, corresponding to the 4′ -OEt (4k), 3′ -F-4′ -OEt (4n) and 3′ -Cl-4′ -OEt (4o) phenyl 
analogues were significantly more active than the rest of the derivatives, with IC50 values of 1.8–34.7, 1.5–14.2 and 
0.4–3.8 nM, respectively, in the seven cell lines, as compared with 1-3100, 210-5400 and 2–62.3 nM for the ref-
erence compounds 1a, 3b and 3c. With average IC50 values of 7.1, 7.2 and 1.3 nM for 4k, 4n and 4o, respectively, 
compound 4o appeared to be the most active compound in the series (for 1a, 3b and 3c, the average IC50 values 
were 523, 1712 and 15 nM, respectively). Derivatives 4k and 4n were 2-fold more active than the 2′ -naphthyl 
derivative 3c, while this latter compound was 12-fold less active than 4o. In addition to these three highly active 
new compounds, the 3′ -F-4′ -OMe and 4′ -n-OPr phenyl derivatives 4d and 4q were more active than CA-4 against 
HT-29, A549 and RS4;11 cells.
The replacement of the methoxy moiety of 3b with a less electron-donating methyl group at the 4′ -position 
of the phenyl ring (4a) caused a 2–12 fold drop in antiproliferative activity in six of the seven cancer cell lines 
relative to 3b (the exception was the HL-60 cell line). The 4′ -ethyl homologue 4b was less active than its methyl 
counterpart 4a against four of the seven cancer cell lines. Replacement of 4′ -OMe group (3b) with a weak 
electron-releasing 4′ -methylsulfanyl moiety (4c) reduced antiproliferative activity in five of the cancer cell lines 
relative to 3b.
Relative to the activity of 3b, the insertion of an additional electron-withdrawing or electron-releasing group 
on the 3′ -position of the 4′ -methoxyphenyl ring had varying effects on antiproliferative activity. The introduc-
tion of a strong electron-withdrawing fluorine, to furnish the 3′ -F-4′ -OMe phenyl derivative 4d, resulted in 
increased antiproliferative activity in all seven cell lines. The introduction of chlorine or methyl substituents at 
the meta-position of 3b, to yield 4e and 4f, respectively, generally resulted in lower activity relative to 3b. By inter-
changing the positions of the methoxy and methyl groups in 4f, we synthesized the corresponding 3′ -OMe-4′ -Me 
regioisomeric analogue 4g, which showed substantially reduced activity relative to 4f.
Adding an extra methoxy group, to furnish the 3′ ,4′ -diOMe derivative 4i, led to a dramatic decrease in 
potency against all seven cell lines. A second methyl group, to furnish the 3′ ,5′ -diMe-4′ -OMe derivative 4h, also 
caused a substantial loss in activity relative to 4f, as did the electron-withdrawing but bulky trifluoromethoxy 
moiety (compound 4j).
Compd 
IC50 (nM)a
HeLa HT-29 A549 MCF-7 Jurkat RS4;11 HL-60
3b 210 ± 10.2 233 ± 52 1013 ± 104 230 ± 55 133 ± 31 5400 ± 950 4766 ± 120
3c 2.0 ± 0.14 3.6 ± 0.9 7.1 ± 1.5 4.6 ± 2.3 2.5 ± 0.9 62.3 ± 10.3 24.0 ± 12.1
4a 1260 ± 172 1915 ± 354 4733 ± 328 2800 ± 721 760 ± 136 > 10000 2100 ± 252
4b 1985 ± 126 1400 ± 200 7000 ± 1153 2090 ± 374 4569 ± 758 5678 ± 259 4800 ± 451
4c 337 ± 48 330 ± 36 5600 ± 352 1363 ± 349.8 407 ± 24 800 ± 58 333 ± 41
4d 51 ± 6.5 112 ± 15 121 ± 56 74 ± 17 90 ± 23 217 ± 46 29 ± 9.5
4e 263 ± 39 647 ± 83 2600 ± 422 666 ± 231 365 ± 25 715 ± 148 453 ± 14
4f 330 ± 25 377 ± 33 4717 ± 509 509 ± 25 136 ± 38 475 ± 106 413 ± 27
4g 623 ± 98 > 10000 > 10000 > 10000 4933 ± 536 2567 ± 784 > 10000
4h 9157 ± 1593 > 10000 > 10000 > 10000 > 10000 > 10000 3466 ± 467
4i > 10000 > 10000 > 10000 > 10000 > 10000 > 10000 3933 ± 517
4j > 10000 > 10000 > 10000 > 10000 6633 ± 338 > 10000 > 10000
4k 3.7 ± 0.12 1.8 ± 0.8 1.9 ± 1.0 1.5 ± 0.2 1.2 ± 0.5 34.7 ± 0.0 4.8 ± 1.9
4l > 10000 > 10000 > 10000 > 10000 > 10000 > 10000 > 10000
4m > 10000 > 10000 > 10000 > 10000 > 10000 > 10000 > 10000
4n 1.5 ± 0.32 7.5 ± 1.2 14 ± 2.3 3.4 ± 0.38 12 ± 6.6 8.6 ± 1.1 3.5 ± 0.73
4o 3.8 ± 0.7 0.4 ± 0.06 0.57 ± 0.17 0.7 ± 0.06 0.9 ± 0.2 1.2 ± 0.7 1.8 ± 0.6
4p 48 ± 2.5 174 ± 16 228 ± 81 69 ± 7.0 127 ± 27 85 ± 20 12 ± 2.5
4q 2.9 ± 0.8 15 ± 1.3 63 ± 18.1 1.7 ± 0.6 42 ± 3.9 91 ± 8.9 63.0 ± 17.6
CA-4 4 ± 1 180 ± 30 3100 ± 100 5 ± 0.6 0.8 ± 0.2 370 ± 100 1 ± 0.2
Table 1.  In vitro cell growth inhibitory effects of compounds 3b, 3c, 4a–q and CA-4 (1a). aIC50 = compound 
concentration required to inhibit tumor cell proliferation by 50%. Data are expressed as the mean ± SE from the 
dose-response curves of at least three independent experiments.
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We found that replacement of methoxy with ethoxy at the para-position of the phenyl ring, to furnish deriva-
tive 4k, improved antiproliferative activity 57-933-fold relative to 3b. Moving the ethoxy group from the para- to 
the meta- or ortho- position, to furnish isomeric derivatives 4l and 4m, respectively, led to a dramatic drop of 
potency as compared with 4k. Lengthening the 4′ -substituent further, to an isopropoxy group (4q) led to reduced 
activity relative to 4k in five cell lines.
With the 4′ -methoxy and 4′ -ethoxy phenyl derivatives 3b and 4k, respectively, increasing the size of the 4′ 
substituent modestly with either a by the replacement of the 4′ -methylsulfanyl (4c) or a 4′ -ethylsulfanyl (4p) 
substituent led to a loss in activity. Compound 4c was less active than 3b in five of the seven cell lines, and 4p 
was less active than 4k in all seven lines. Because the para-ethoxy phenyl moiety of 4k was favorable for potency, 
we evaluated the effect on activity by the introduction of a fluorine or chlorine at the meta-position, resulting in 
the 3′ -F-4′ -OEt and 3′ -Cl-4′ -OEt phenyl derivatives 4n and 4o, respectively. With the fluorine substituent (4n), 
activity improved in only three of the cell lines, while, with the chloro substituent (4o), activity improved in six of 
the cell lines. Moreover, 4o was more active than 4n in all cell lines except the HeLa cells. In contrast, the opposite 
effect was observed for the 3′ -F-4′ -OMe and 3′ -Cl-4′ -OMe phenyl derivatives 4d and 4e, respectively, where the 
fluoro derivative (4d) was more active than the chloro derivative (4c) in all seven cell lines. These results imply 
that the 3′ -hydroxy-4′ -ethoxyphenyl moiety of CA-4 (B-ring) can be replaced by a 3′ -chloro-4′ -ethoxyphenyl or 
a 3′ -fluoro-4′ ethoxyphenyl group.
Evaluation of cytotoxicity in human non-cancer cells.  To obtain a preliminary indication of the cyto-
toxic potential of these derivatives in normal human cells, one of the most active compounds (4o) was evaluated 
in vitro against peripheral blood lymphocytes (PBL) from healthy donors (Table 2). The compound showed an 
IC50 greater than 10 μ M in quiescent lymphocytes, while in the presence of the mitogenic stimulus phytohemato-
aglutinin (PHA), the IC50 decreased to about 0.5 μ M. This value was almost 600 times higher than that observed 
against the Jurkat lymphoblastic cell line. These results indicate that 4o has a significant effect in rapidly prolif-
erating cells but not in quiescent cells, as previously observed for other antimitotic derivatives developed by our 
group21.
Inhibition of tubulin polymerization and colchicine binding.  To investigate whether the antipro-
liferative activities of compounds 4k, 4n–o and 4q derived from an interaction with tubulin, these agents were 
evaluated for their inhibition of tubulin polymerization and for effects on the binding of [3H]colchicine to tubu-
lin (Table 3)22. For comparison, CA-4 and 3c were examined in contemporaneous experiments as reference 
compounds. All tested compounds strongly inhibited tubulin assembly, and the IC50 values of 0.63 and 0.57 μ M 
obtained with 4k and 4n, respectively, were among the lowest ever observed in this assay and half that obtained 
in simultaneous experiments with CA-4 (IC50 = 1.3 μ M). While compounds 4k and 4n were the best inhibitors 
of tubulin assembly, about 1.5-fold more potent than 4o, this latter compound, as described above, was more 
effective as an inhibitor of cell growth. Compound 4o was also 1.5-fold more potent than CA-4 as an inhibitor 
of tubulin assembly. Compound 4q was as active as CA-4, while 3c was less active. Compounds 4k, 4n–o and 4q 
were from 1.2- to 3-fold more active than the 2-naphthyl derivative 3c as inhibitors of tubulin assembly.
In the colchicine binding studies, compounds 4k, 4n, 4o and 4q strongly inhibited binding of colchicine to 
tubulin (over 50% inhibition when present in the reaction mixture at the same concentration as colchicine). Even 
when present at 1 μ M, 20% of the colchicine concentration, 4k, 4n and 4o inhibited colchicine binding by over 
50%. None, however, was quite as potent as CA-4, which in these experiments inhibited colchicine binding by 
99% at 5 μ M and by 87% at 1 μ M.
Cell line IC50 (μM)a
PBLrestingb > 10
PBLPHAc 0.52 ± 0.04
Table 2.  Cytotoxicity of 4o for human PBL. aCompound concentration required to reduce cell growth by 
50%. bPBL not stimulated with PHA. cPBL stimulated with PHA.
Compound Tubulin assemblya IC50 ± S.D. (μ M)
Colchicine bindingb % inhibition ± S.D.
5 μM drug 1 μ M drug
3c 1.8 ± 0 65 ± 4 n.d.
4k 0.63 ± 0 86 ± 0.5 64 ± 3
4n 0.57 ± 0 89 ± 0.3 71 ± 3
4o 0.87 ± 0 81 ± 0.3 54 ± 1
4q 1.4 ± 0.1 67 ± 0.5 n.d.
CA-4 (1a) 1.3 ± 0.1 99 ± 0.2 87 ± 2
Table 3.  Inhibition of tubulin polymerization and colchicine binding by compounds 3c, 4k, 4n–o, 4q and 
CA-4. n.d. = not determined. aInhibition of tubulin polymerization. Tubulin was at 10 μ M. bInhibition of [3H]
colchicine binding. Tubulin and colchicine were at 1 and 5 μ M concentrations, respectively.
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Compounds 4k, 4n and 4o have activity superior to that of CA-4 as inhibitors of tubulin polymerization 
and are also highly active as inhibitors of colchicine binding to tubulin. While this group of compounds were 
all potent in the biological assays (inhibition of cell growth, tubulin assembly and colchicine binding), correla-
tion between the three assay types was imperfect. In general, in these experiments, inhibition of [3H]colchicine 
binding correlated more closely with inhibition of tubulin assembly than with antiproliferative activity. When 
comparing inhibition of tubulin polymerization versus antiproliferative activity, we found a positive correlation 
for most, but not all, of the active compounds. Thus, while compound 4o was generally more active than 4k and 
4n as antiproliferative agent, these latter two molecules were 1.5-fold more active than 4o in the tubulin assembly 
assay. Also compound 4q was as active as CA-4 as inhibitor of tubulin polymerization, although this derivative 
was less active in its effects on cell growth against Jurkat, RS4;11 and HL-60 cells.
Molecular modeling studies.  A series of molecular docking simulations using PLANTS, with the 
chemplp scoring function, were performed on compounds 3c, 4k, 4n, 4o and 4q to investigate their binding 
mode in the colchicine site of tubulin. The proposed binding mode for all the derivatives was consistent with 
that previously reported for the triazole family21, and it was very similar to that observed for the co-crystallized 
DAMA-colchicine. With all derivatives, the trimethoxyphenyl ring is in proximity to β Cys241. The phenyl ring 
with different substituents occupied a small hydrophobic subpocket (Fig. 3), making potential hydrophobic inter-
actions with the surrounding amino acids (e.g., β Met259). Tubulin polymerization inhibition appeared to be 
influenced by the substituent on the phenyl ring, but the explanation for this observation was not evident from 
the docking studies. For this reason, we investigated the role of the substituent on the phenyl through a series 
of molecular dynamic (MD) simulations on selected compounds (3c, 4k, 4o, 4q) using the Desmond software 
package for MD simulation. We then evaluated the compounds relative binding free energies (Δ Gbinding) using 
the Prime/MM-GBSA based calculation method23,24. After an initial 3 ns of equilibration, all the protein-ligand 
systems reached stability (Fig. S1). We therefore considered only the remaining 7 ns of the simulation in our 
analysis. The predicted binding mode, and, in particular, the position of the trimethoxyphenyl ring, was main-
tained by all derivatives during the entire simulation, confirming the reliability of the docking studies. The lowest 
calculated Δ Gbinding was found for compound 4k, the ethoxy derivative, whereas derivative 3c showed the highest 
estimated energy value. The linear relationship between the estimated Δ Gbinding and the IC50 for inhibition of 
tubulin polymerization was found for all the simulations performed (Table 4 and Fig. S2). The hydrophobic 
subpocket can accommodate the different substituted phenyl rings, but only the ethoxy derivatives (4k and 4o) 
were able to fit into it properly, thereby conferring stability to the protein-ligand system and yielding low energy 
values. The insertion of a second, more hindered, substituent at position 3, as in compound 4o (4-ethoxy-3-Cl 
derivative), slightly reduced the potency of inhibition of tubulin polymerization, and, indeed, a higher calculated 
Δ Gbinding value was found. Larger groups in a para position, such as in the propoxy (4q) and the naphtyl (3c) 
derivatives, could be accommodated in the pocket but with a higher protein-ligand Δ Gbinding, which is consistent 
Figure 3. Proposed binding for compound 4k (in grey) in the colchicine site. Co-crystallized DAMA-
colchicine is shown in green. The hydrophobic subpocket is highlighted with a red surface.
Compound ∆Gbinding (kJ/mol)a IC50 (μM)
3c − 71.543 1.8
4k − 98.652 0.63
4o − 89.506 0.87
4q − 78.846 1.4
Table 4.  Calculated ligand-interaction energies for the compounds analyzed by Molecular Dynamics and 
inhibition of tubulin polymerization IC50 values. aAverage values of Δ Gbinding calculated excluding the first 
3ns of MD in which the protein-ligand system reached stability.
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with the reduced capacity of these compounds to inhibit tubulin polymerization. The MD simulation results 
confirmed the importance of the trimethoxyphenyl ring for the interaction of the ligand with the colchicine site. 
Furthermore, the binding energy calculations confirmed the importance of the hydrophobic sub-pocket in the 
colchicine site and provide a plausible explanation for the different activities observed with the different substit-
uents on the phenyl ring.
Compound 4o induced mitotic arrest of the cell cycle.  The effects of a 24 h treatment with different 
concentrations of 4o on cell cycle progression in Jurkat, and HeLa cells were determined by flow cytometry, fol-
lowing propidium iodide (PI) staining of the cells (Fig. 4, Panels A,B). The compound caused a significant G2/M 
arrest in a concentration-dependent manner in the cell lines tested, with a rise in G2/M cells occurring at a con-
centration as low as 25 nM, while at the highest concentration more than 80% of the cells were arrested in G2/M 
in HeLa cells. In the HeLa cells, the G2/M block was accompanied by a significant reduction of both G1 and S 
phase cells. In order to determine whether 4o was able to block cells at the mitotic phase (M), cells were stained 
with an immunofluorescent antibody to p-histone H3, a well known mitotic marker25, as well as PI, and analyzed 
by flow cytometry. As shown in Fig. 4 (Panel C), in which representative histograms are presented, Hela cells 
Figure 4. Percentage of cells in each phase of the cell cycle in HeLa (Panel A) and Jurkat cells (Panel B) treated 
with compound 4o at the indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed 
by flow cytometry as described in the Experimental Section. Data are represented as mean ± SEM of three 
independent experiments. Representative histograms of mitotic cells with phosphorylated histone-H3 (Panel C) 
and quantitative analysis (Panel D) after treatment with 4o at the indicated concentrations in HeLa cells. Data 
are represented as mean ± SEM of two independent experiments.
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arrested in M phase by treatment with 4o are readily distinguished from G2 cells by the higher level of p-histone 
H3. In particular, treatment with 4o induced an increase in the percentage of mitotic cells from the 2% observed 
in untreated cells to about 30% with both 50 and 100 nM 4o at 24 h (Fig. 4, Panel D).
Compound 4o  induced alteration  in both  cell  cycle and  spindle assembly  checkpoint  
proteins.  We investigated the effects of 4o on the expression of several proteins involved in regulation of the 
cell cycle and in spindle assembly. Cyclin B1 is involved in the G2 to M transition as a complex with cdc2, and the 
activation of the cdc2/cyclin B1 complex through cdc25c-dependent dephosphorylation of phospho-cdc2 and 
phosphorylation of cyclin B1 triggers cells to enter mitosis26,27. As shown in Fig. 5 (Panel A) a marked increase 
of cyclin B1 was observed after a 24 h treatment with 50 nM 4o. At this time point, total cdc25c expression was 
strongly reduced, while more slowly migrating forms of cdc25c appeared both at 24 and 48 h, indicating changes 
in the phosphorylation state of this protein. Moreover, in good agreement, the expression of phosphorylated cdc2 
strongly decreased after both 24 and 48 h treatments. Thus, our results indicate that cdc2/cyclin B1 complexes 
failed to be activated, preventing cells from exiting mitosis, which would eventually lead to apoptotic cell death.
Formation of the microtubular mitotic spindle is of fundamental importance in mitosis for the correct segre-
gation of chromosomes and a proper mitotic exit. Thus, we also examined the levels of several proteins regulating 
spindle assembly, such as PLK1, MAD2, cdc20 and ROCK128. First, we examined if 4o inhibited the anaphase 
promoting complex/cyclosome (APC/C). To do this, we analyzed the expression of cdc20, which is associated 
with its inhibitory protein MAD2. Although the level of cdc20 remained unaffected after a 24 h treatment, MAD2 
expression was substantially decreased at both 24 and 48 h, suggesting that 4o would inhibit the formation of the 
MAD2/cdc20 checkpoint complex and thus impair the spindle checkpoint machinery.
Polo-like kinase (PLK1) has many functions in mitosis, including centrosome maturation, kinetochore-spindle 
attachment, chromosome segregation and cytokinesis29. Moreover, PLK1 can phosphorylate and activate 
cdc25c30. We observed a marked increase in the phosphorylation of PLK1 after a 24 h treatment with 4o, when 
mitotic arrest occurred, and then this effect disappeared at 48 h. This was probably due to DNA damage, which 
reduces PLK1 phosphorylation31. Indeed, examining the expression of phosphorylated histone H2A.X at Ser139 
(γ H2A.X), a well known marker of DNA damage32, we observed (Fig. 5, Panel B) a remarkable increase of the 
phosphorylation of γ H2A.X, suggesting that DNA damage occur following treatment with 4o.
ROCK1 (Rho-associated coiled-coil kinase1) is a protein involved in proper microtubule dynamics and cen-
trosome integrity during mitosis, and, in addition, it is also involved in cell motility and contractility33. It is also 
interesting to note that ROCK1 is cleaved by caspase-3 during apoptosis and is responsible for the formation 
of apoptotic blebs34. As shown in Fig. 5 (Panel A), western blot analysis showed that cleaved bands of ROCK1 
appeared after a 48 h treatment with 4o. Altogether, our results showed that 4o induced cell cycle arrest at the 
mitotic phase and impaired spindle checkpoint functions that ultimately should lead to apoptosis.
Compound 4o induced apoptosis.  To evaluate the induction of apoptosis by compound 4o in two cell 
lines (HeLa and Jurkat), we used an annexin-V/PI assay. Dual staining for annexin-V and with PI permits 
Figure 5. Effect of 4o on cell cycle and spindle assembly checkpoint proteins (Panel A), and expression of 
p-H2A.XSer139 (Panel B). HeLa cells were treated for 24 or 48 h with the indicated concentrations of 4o. The cells 
were harvested and lysed for detection of the expression of the indicated protein by western blot analysis. To 
confirm equal protein loading, each membrane was stripped and reprobed with anti-β -actin antibody.
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discrimination between live cells (annexin-V−/PI−), early apoptotic cells (annexin-V+/PI−), late apoptotic cells 
(annexin-V+/PI+) and necrotic cells (annexin-V−/PI+). As shown in Fig. 6, both HeLa (Panels A,B) and Jurkat 
(Panels C,D) cells treated with 4o showed a significant accumulation of annexin-V positive cells after a 24 h 
treatment at the lowest concentration used (50 nM). The percentage of apoptotic cells increased further after 48 h 
in comparison with untreated Jurkat cells, whereas, in the HeLa cells, we observed a marked increase of necrotic 
cells, indicating that the compound at this time induced massive cellular death.
Compound 4o induced apoptosis through the mitochondrial pathway.  Mitochondria play an 
essential role in the propagation of apoptosis35. It is well established that, at an early stage, apoptotic stimuli 
alter the mitochondrial transmembrane potential (Δ ψ mt). Δ ψ mt was monitored by the fluorescence of the dye 
JC-1. In normal conditions (high Δ ψ mt), JC-1 displays a red fluorescence (590 nm). Both HeLa and Jurkat cells 
treated with 4o (50, 100 and 250 nM) exhibited a remarkable increase in the percentage of cells with low Δ ψ mt 
(Fig. 7, Panels A,C). This occurred in a time- and concentration-dependent fashion, and, in both cell lines, a sig-
nificant increase was observed after a 6 h treatment. The disruption of Δ ψ mt is associated with the appearance of 
annexin-V positivity in the treated cells when they are in an early apoptotic stage. In fact, the dissipation of Δ ψ mt 
is characteristic of apoptosis and has been observed with both microtubule stabilizing and destabilizing agents, 
including CA-4, in different cell types21,36,37.
It is also well known that dissipation of mitochondrial potential is associated with mitochondrial production 
of ROS38. Superoxide anion is produced by mitochondria due to a shift from the normal 4-electron reduction 
of O2 to a 1-electron reduction when cytochrome c is released from mitochondria upon apoptosis. Therefore, 
we investigated whether ROS production increased after treatment with compound 4o. We utilized the dye 
2,7-dichlorodihydrofluorescein diacetate (H2-DCFDA), which is oxidized to the fluorescent compound dichlor-
ofluorescein (DCF) upon ROS induction.
The results shown in Fig. 7 (Panels B,D), indicate that 4o induced the production of large amounts of ROS 
in comparison with control cells, in both Jurkat and HeLa cells, and this agrees with the dissipation of Δ ψ mt 
described above. In fact, the ROS increase was detected only after mitochondrial depolarization, indicating that 
the ROS are produced as a consequence of mitochondrial damage.
Compound 4o induced caspase-dependent apoptosis.  To further study the apoptotic process 
induced by 4o, we analyzed by immunoblot the expression of caspase-3 and its substrate poly(ADP)ribose pol-
ymerase (PARP). We treated HeLa cells with different concentrations (50, 100 and 250 nM) of compound 4o 
for 24 and 48 h. As shown in Fig. 8, we observed an activation of the effector caspase-3, as demonstrated by the 
Figure 6. Flow cytometric analysis of apoptotic cells after treatment of HeLa (Panels A,B) and Jurkat (Panels C,D) 
cells with 4o at the indicated concentrations after incubation for 24 (Panels A,C) or 48 h (Panels B,D). The cells 
were harvested and labeled with annexin-V-FITC and PI and analyzed by flow cytometry.
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appearance of its cleaved fragments, in particular after the 48 h treatment. In good agreement, we observed the 
cleavage of PARP, a caspase-3 substrate. PARP cleavage is a typical marker of apoptosis. It is worth noting to note 
that these effects occurred at all the 4o concentrations used.
Figure 7. Assessment of mitochondrial membrane potential (Δ ψ mt) and production of ROS after treatment 
of HeLa (Panels A,B) or Jurkat (Panels C,D) cells with compound 4o. Cells were treated with the indicated 
concentration of compound for 24 or 48 h and then stained with the fluorescent probe JC-1 for analysis of 
mitochondrial potential or H2-DCFDA for the evaluation of ROS levels. Cells were then analyzed by flow 
cytometry as described in the experimental section.
Figure 8. Western blot analysis of caspase-3, PARP, Bcl-2 and Mcl-1 after treatment of HeLa cells with 4o at 
the indicated concentrations and for the indicated times. To confirm equal protein loading, each membrane 
was stripped and reprobed with anti-β -actin antibody.
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We also investigated the expression of two anti-apoptotic proteins, specifically Mcl-1 and Bcl-2. Mcl-1 is a 
member of the Bcl-2 family of anti-apoptotic proteins. Mcl-1 is overexpressed in many cancers and has been 
implicated in the apoptotic response to multiple stimuli. Recently, it was reported that sensitivity to antimitotic 
drugs is regulated by Mcl-1 levels39. Bcl-2 controls the apoptotic machinery and plays a central role in mitochon-
drial membrane permeabilization40. As shown in Fig. 8, both Mcl-1 and Bcl-2 undergo a dramatic decrease after 
a 24 h treatment at all compound concentrations examined, indicating that 4o induced downregulation of these 
proteins to disable their anti-apoptotic function.
Tumor growth was significantly inhibited by 4o in a mouse allograft tumor model.  To elucidate 
its antitumor effect in vivo, 4o was administered by the intraperitoneal route each other day, at different doses (1, 3 
and 7.5 mg/kg) in a tumor model developed in mice41. As reference compound, CA-4P (1b) was used at 30 mg/kg. 
The BL6-B16 mouse melanoma cell line, injected subcutaneously in syngeneic C57/BL6 mice, is able to proliferate 
and generate tumor masses.
As shown in Fig. 9, after six days of treatment (doses administered on days 9, 11 and 14), 4o was able to signif-
icantly reduce tumor burden in a dose-dependent manner, even at the lowest dose tested (1 mg/kg). We observed 
a reduction of tumor mass of 26.0, 32.2 and 45.8% at the doses of 1, 3.5 and 7.5 mg/kg, respectively. The reference 
compound CA-4P (1b) at 30 mg/kg induced only a 26.5% reduction of tumor mass. Notably, the in vivo efficacy 
clearly indicates an increased antitumor efficacy of 4o as compared with CA-4P. Even at the highest dose, 4o did 
not present any sign of toxicity and did not cause a decrease in animal body weight (data not shown).
Conclusions
The structural refinement of compounds 3a–c led to the discovery of a novel series of synthetic inhibitors of 
tubulin polymerization with general structure 4, based on the 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-aryl-1H-imidazole 
molecular skeleton. These molecules were prepared in mild conditions via a palladium-catalyzed Suzuki cross 
coupling reaction, starting from an easily accessible key intermediate, 1-(3′ ,4′ ,5′ -trimethoxyphenyl)-2-bromo-
1H-imidazole. We retained the 3′ ,4′ ,5′ -trimethoxyphenyl moiety as ring A throughout the present investigation, 
and a SAR was elucidated with several variations of substituents on the second aryl ring at the 2-position of the 
imidazole nucleus.
The best results for inhibition of antiproliferative activity was obtained with 4′ -OEt, 3′ -F-4′ -OEt and 
3′ -Cl-4′ -OEt phenyl analogues 4k, 4n and 4o, respectively. In particular, compound 4o exhibited the strong-
est growth inhibitory activity in the series, with IC50 values ranging from 0.4 to 3.8 nM against seven cancer 
cells lines. Compound 4o was also more potent as an antiproliferative agent than the corresponding 1-(3′ ,4′ , 
5′ -trimethoxyphenyl)-5-(3′ -chloro-4′ -ethoxyphenyl) triazole previously published by us16d. This compound has 
IC50 values ranging from 3 to 20 nM, as compared with the range 0.4–3.8 nM obtained with 4o in the same seven 
cell lines.
Importantly, 4o showed very low cytotoxicity in proliferating lymphocytes obtained from healthy volunteers, 
and it was practically ineffective in resting lymphocytes, suggesting that it preferentially was toxic in proliferating 
cells as compared with quiescent cells. In this context, further experiments will be needed to better characterize 
the toxicological profile of 4o.
Compound 4o strongly inhibited tubulin assembly, exhibiting activity about 1.5-2-fold greater than that of 
CA-4, while in the colchicine binding studies, it was slightly less potent than CA-4, which, in these experiments, 
inhibited colchicine binding by 99%. These results were supported by a series of molecular docking and MD 
simulations.
The pharmacological investigation demonstrated that 4o was able to induce mitotic arrest even at low con-
centrations and caused a strong impairment of both cell cycle and spindle assembly checkpoint proteins. This 
Figure 9. Inhibition of mouse allograft growth in vivo by compound 4o. Male C57BL/6 mice were injected 
subcutaneously at their dorsal region with 107 BL6-B16 murine melanoma cells. Tumor-bearing mice were 
administered the vehicle, as control, or 1, 3 or 7.5 mg/kg of 4o or CA-4P as reference compound at the dose 
of 30 mg/kg. Injections were given intraperitoneally at the days indicated by the arrows. Data are presented as 
mean ± SEM of tumor volume at each time point for 5 animals per group. * p < 0.05, * * p < 0.01 * * * p < 0.001 vs. 
control.
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ultimately led to a massive apoptosis that follow the mitochondrial pathway, as demonstrated by the induction 
of mitochondrial depolarization. Finally, this excellent pharmacological profile was confirmed through in vivo 
experiments in which the compound was very effective in reducing tumor mass at doses 3-30 times lower in com-
parison with CA-4P. In short, our findings demonstrate that 4o is a promising antitumor compound that warrants 
further preclinical development.
Experimental Section
Chemistry. Materials and methods.  1H NMR and 13C NMR spectra were recorded in CDCl3 solution 
with a Varian Mercury Plus 400 spectrometer at 400 MHz and 100 MHz, respectively. Peak positions are given 
in parts per million (δ ) downfield from tetramethylsilane as internal standard, and J values are given in hertz. 
Positive-ion electrospray ionization (ESI) mass spectra were measured on a double-focusing Finnigan MAT 95 
instrument with BE geometry. Melting points (mp) were determined on a Buchi-Tottoli apparatus and are uncor-
rected. The purity of tested compounds was determined by combustion elemental analyses conducted by the 
Microanalytical Laboratory of the Chemistry Department of the University of Ferrara with a Yanagimoto MT-5 
CHN recorder elemental analyzer. All tested compounds yielded data consistent with a purity of at least 95% as 
compared with the theoretical values. TLC was performed on silica gel (precoated F254 Merck plates), and com-
pounds were visualized with aqueous KMnO4. Flash column chromatography was performed using 230–400 
mesh silica gel and the indicated solvent system. Organic solutions were dried over anhydrous Na2SO4. All com-
mercial chemicals and solvents were reagent grade and were used without further treatment.
Preparation of 1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (5). A stirred suspension of imidazole (954 mg, 
14 mmol), 5-bromo-1,2,3-trimethoxybenzene (2.47 g., 10 mmol), CuI (381 mg, 2 mmol) and Cs2CO3 (6.5 g., 
20 mmol) in DMF (20 mL) was evacuated and then back filled with Ar, and this sequence was repeated three 
times. The reaction mixture was stirred for 30 min at room temperature and then heated at 120 °C under Ar 
for 36 h. After being cooled at room temperature, the reaction mixture was diluted with a mixture of EtOAc 
(40 mL) and water (10 mL). The organic phase was washed with water (3 × 10 mL), brine (10 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography on sil-
ica gel (EtOAc-MeOH 9-1 v/v as eluent) to furnish the desired product 5 as a yellow oil. Yield: 77%. 1H-NMR 
(400 MHz, d6-DMSO) δ : 3.67 (s, 3H), 3.86 (s, 6H), 6.92 (s, 2H), 7.08 (m, 1H), 7.74 (m, 1H), 8.23 (m, 1H). MS 
(ESI): [M + 1]+ = 235.2.
Preparation of 2-bromo-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (6). To a solution of 1-(3′ ,4′ ,5′ 
-trimethoxyphenyl)-1H-imidazole (1.17 g, 5 mmol) in dry acetonitrile (50 mL), NBS (980 mg, 5.5 mmol) was 
added, and the reaction mixture was heated at reflux for 3 h. The solvent was removed under reduced pressure, 
and the residue was diluted with EtOAc (30 mL), and the EtOAc solution was washed with 5% aqueous NaHCO3 
(10 mL), water (10 mL), and brine (50 mL), dried (Na2SO4) and concentrated. The residue was purified by column 
chromatography on silica gel (EtOAc-petroleum ether 6-4 v/v), to furnish the desired product 6 as a pink solid, 
mp 145–147 °C. Yield: 81%. 1H-NMR (400 MHz, d6-DMSO) δ : 3.71 (s, 3H), 3.81 (s, 6H), 6.80 (s, 2H), 7.09 (d, 
J = 1.4 Hz, 1H), 7.56 (d, J = 1.4 Hz, 1H). 13C-NMR (100 MHz, d6-DMSO) δ : 56.16 (2C), 60.01, 104.18 (2C), 118.67, 
124.82, 129.48 (2C), 132.28, 137.42, 152.90. MS (ESI): [M + 1]+ = 312.9 and 314.8.
General procedure A for the synthesis of compounds 4a–q. A stirred solution of 6 (156 mg, 0.5 mmol) and the 
appropriate phenylboronic acid (0.75 mmol) in 1,4-dioxane (6 mL containing 1 drop of water) was degassed under 
a stream of N2 over 10 min, then treated with PdCl2(DPPF) (41 mg, 0.05 mmol) and CsF (190 mg, 1.25 mmol). The 
reaction mixture was heated under N2 at 45 °C for 30 min, then at 75 °C for 5 h. The reaction mixture was cooled 
to ambient temperature, diluted with CH2Cl2 (10 mL), filtered through a pad of celite and evaporated in vacuo. 
The residue was dissolved with CH2Cl2 (15 mL), and the resultant solution was washed sequentially with water 
(5 mL) and brine (5 mL). The organic layer was dried and evaporated, and the residue was purified by flash chro-
matography on silica gel.
1-(3′,4′,5′-Trimethoxyphenyl)-2-p-tolyl-1H-imidazole (4a). Following general procedure A, the crude resi-
due was purified by flash chromatography, using EtOAc-petroleum ether 7-3 as eluent, to furnish 4a as a white 
solid, mp 142–144 °C. Yield: 62%. 1H-NMR (400 MHz, CDCl3) δ : 2.32 (s, 3H), 3.72 (s, 6H), 3.87 (s, 3H), 6.42 (s, 
2H), 7.05 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 1.2 Hz, 1H), 7.21 (d, J = 1.2 Hz, 1H), 7.30 (d, J = 8.8 Hz, 2H). 13C-NMR 
(100 MHz, CDCl3) δ : 21.32, 56.31 (2C), 61.14, 103.63 (2C), 122.69, 127.53, 128.37 (2C), 128.85, 128.94 (2C), 
134.40, 136.53, 138.34, 146.92, 153.58 (2C). MS (ESI): [M + 1]+ = 325.2. Anal. (C19H20N2O3) C, H, N.
2-(4′-Ethylphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4b). Following general procedure A, the crude 
residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish 4b as a white solid, mp 
130–132 °C. Yield: 59%. 1H-NMR (400 MHz, CDCl3) δ : 1.20 (t, J = 7.6 Hz, 3H), 2.61 (q, J = 7.5 Hz, 2H), 3.71 
(s, 6H), 3.87 (s, 3H), 6.40 (s, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 1.2 Hz, 1H), 7.23 (d, J = 1.2 Hz, 1H), 7.31 
(d, J = 8.4 Hz, 2H). 13C-NMR (100 MHz, CDCl3) δ : 15.48, 28.70, 56.30 (2C), 61.14, 103.59 (2C), 122.45, 127.06, 
127.41, 127.73 (2C), 128.52, 128.68, 134.18, 134.62, 144.88, 146.86, 153.57 (2C). MS (ESI): [M + 1]+ = 339.0. 
Anal. (C20H22N2O3) C, H, N.
1-(3′,4′,5′-Trimethoxyphenyl)-2-(4′-(methylthio)phenyl)-1H-imidazole (4c). Following general procedure A, the 
crude residue was purified by flash chromatography, using ethyl acetate-petroleum ether 8-2 as eluent, to furnish 
4c as a white solid, mp 158–160 °C. Yield: 79%. 1H-NMR (400 MHz, CDCl3) δ : 2.45 (s, 3H), 3.73 (s, 6H), 3.88 (s, 
3H), 6.43 (s, 2H), 7.12 (m, 3H), 7.21 (d, J = 1.2 Hz, 1H), 7.34 (d, J = 8.8 Hz, 2H). 13C-NMR (100 MHz, CDCl3) 
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δ : 15.39, 56.37 (2C), 61.15, 103.64 (2C), 122.96, 125.72 (2C), 126.88, 128.67 (2C), 128.98, 134.29, 137.90, 139.26, 
146.34, 153.69 (2C). MS (ESI): [M + 1]+ = 357.2. Anal. (C19H20N2O3S) C, H, N.
2-(3′-Fluoro-4′-methoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4d). Following general procedure 
A, the crude residue was purified by flash chromatography, using ethyl acetate as eluent, to furnish 4d as a white 
solid, mp 126–127 °C. Yield: 68%. 1H-NMR (400 MHz, CDCl3) δ : 3.76 (s, 6H), 3.87 (s, 3H), 3.89 (s, 3H), 6.44 
(s, 2H), 6.84 (t, J = 8.4 Hz, 1H), 7.11 (d, J = 1.2 Hz, 1H), 7.13 (m, 1H), 7.20 (d, J = 1.2 Hz, 1H), 7.22 (dd, J = 12.8 
and 2.4 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ : 56.38 (2C), 60.46, 61.17, 103.68 (2C), 112.83, 116.12, 123.00, 
123.47, 124.46, 128.91, 134.10, 138.05, 145.49, 147.92, 153.05, 153.74 (2C). MS (ESI): [M + 1]+ = 359.2. Anal. 
(C19H19FN2O4) C, H, N.
2-(3′-Chloro-4′-methoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4e). Following general procedure 
A, the crude residue was purified by flash chromatography, using ethyl acetate-petroleum ether 7-3 as eluent, to 
furnish 4e as a white solid, mp 176–178 °C. Yield: 54%. 1H-NMR (400 MHz, CDCl3) δ : 3.75 (s, 6H), 3.86 (s, 3H), 
3.89 (s, 3H), 6.44 (s, 2H), 6.79 (d, J = 8.6 Hz, 1H), 7.12 (d, J = 1.2 Hz, 1H), 7.22 (m, 2H), 7.56 (d, J = 2.2 Hz, 1H). 
13C-NMR (100 MHz, CDCl3) δ : 56.24, 56.47 (2C), 61.21, 103.76 (2C), 111.53, 122.41, 122.97, 127.23, 127.92, 
128.40, 129.12, 130.35, 133.86, 145.19, 153.81 (2C), 155.26. MS (ESI): [M + 1]+ = 375.2. Anal. (C19H19ClN2O4) 
C, H, N.
2-(4′-Methoxy-3′-methylphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4f). Following general procedure 
A, the crude residue was purified by flash chromatography, using EtOAc-petroleum ether 7-3 as eluent, to furnish 
4f as a white solid, mp 128–130 °C. Yield: 62%. 1H-NMR (400 MHz, CDCl3) δ : 2.13 (s, 3H), 3.72 (s, 6H), 3.78 (s, 
3H), 3.86 (s, 3H), 6.43 (s, 2H), 6.64 (d, J = 8.4 Hz, 1H), 7.05 (dd, J = 8.4 and 2.4 Hz, 1H), 7.09 (d, J = 1.2 Hz, 1H), 
7.17 (d, J = 1.2 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ : 16.19, 55.36, 56.35 (2C), 61.14, 
103.75 (2C), 109.33, 122.41, 126.50, 127.03, 128.65 (2C), 130.97, 134.56, 137.76, 146.92, 153.55 (2C), 157.96. MS 
(ESI): [M + 1]+ = 355.2. Anal. (C20H22N2O4) C, H, N.
2-(4′-Methyl-3′-methoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4g). Following general procedure 
A, the crude residue was purified by flash chromatography, using EtOAc-petroleum ether 7-3 as eluent, to fur-
nish 4g as a colorless oil. Yield: 59%. 1H-NMR (400 MHz, CDCl3) δ : 2.17 (s, 3H), 3.70 (s, 3H), 3.74 (s, 6H), 3.87 
(s, 3H), 6.46 (s, 2H), 6.79 (dd, J = 7.6 and 1.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.05 (d, J = 1.2 Hz, 1H), 7.12 (d, 
J = 1.2 Hz, 1H), 7.21 (d, J = 1.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ : 16.12, 55.27, 56.39 (2C), 61.12, 103.84 
(2C), 110.04, 120.32, 122.87, 127.13, 128.77, 122.87, 130.27, 134.54, 137.87, 146.91, 153.63 (2C), 157.43. MS (ESI): 
[M + 1]+ = 355.1. Anal. (C20H22N2O4) C, H, N.
2-(4′-Methoxy-3′,5′-dimethylphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4h). Following general pro-
cedure A, the crude residue was purified by flash chromatography, using EtOAc-petroleum ether 7-3 as eluent, to 
furnish 4h as a white solid, mp 153–155 °C. Yield: 52%. 1H-NMR (400 MHz, CDCl3) δ : 2.17 (s, 6H), 3.68 (s, 3H), 
3.72 (s, 6H), 3.87 (s, 3H), 6.43 (s, 2H), 7.07 (s, 2H), 7.11 (d, J = 1.2 Hz, 1H), 7.18 (d, J = 1.2 Hz, 1H). 13C-NMR 
(100 MHz, CDCl3) δ : 16.13 (2C), 56.39 (2C), 59.77, 61.17, 103.74 (2C), 122.47, 125.84, 128.79 (2C), 129.12 (2C), 
130.66, 124.37, 137.87, 146.69, 153.54 (2C), 157.32. MS (ESI): [M + 1]+ = 369.2. Anal. (C21H24N2O4) C, H, N.
1-(3′,4′,5′-Trimethoxyphenyl)-2-(3′,4′-dimethoxyphenyl)-1H-imidazole (4i). Following general procedure A, 
the crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4i as a yellow oil. 
Yield: 63%. 1H-NMR (400 MHz, CDCl3) δ : 3.74 (s, 6H), 3.75 (s, 3H), 3.78 (s, 3H), 3.87 (s, 3H), 6.46 (s, 2H), 6.70 
(d, J = 8.6 Hz, 1H), 6.85 (dd, J = 8.6 and 1.8 Hz, 1H), 7.12 (m, 2H), 7.20 (d, J = 1.2 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3) δ : 55.81, 55.91, 56.40, 61.12, 103.83 (2C), 110.62, 111.52, 121.11, 122.74, 123.03, 126.50, 128.72, 134.54, 
137.88, 146.61, 148.56, 152.21, 153.67 (2C). MS (ESI): [M + 1]+ = 371.2. Anal. (C20H22N2O5) C, H, N.
1-(3′,4′,5′-Trimethoxyphenyl)-2-(4′-(trifluoromethoxy)phenyl)-1H-imidazole (4j). Following general procedure 
A, the crude residue was purified by flash chromatography, using EtOAc-petroleum ether 6-4 as eluent, to furnish 
4j as a yellow solid, mp 125–127 °C. Yield: 68%. 1H-NMR (400 MHz, CDCl3) δ : 3.72 (s, 6H), 3.88 (s, 3H), 6.41 
(s, 2H), 7.12 (dd, J = 8.8 and 2.8 Hz, 2H), 7.16 (d, J = 1.2 Hz, 1H), 7.23 (d, J = 1.2 Hz, 1H), 7.46 (dd, J = 8.8 and 
2.8 Hz, 2H). 13C-NMR (100 MHz, CDCl3) δ : 56.32 (2C), 61.16, 103.53 (2C), 118.2 (q, J = 262 Hz), 120.67 (2C), 
123.26, 129.09, 129.22, 129.94 (2C), 133.92, 138.04, 145.38, 149.19, 153.78 (2C). MS (ESI): [M + 1]+ = 395.1. 
Anal. (C19H17F3N2O4) C, H, N.
2-(4′-Ethoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4k). Following general procedure A, the 
crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4k as a white solid, mp 
132–134 °C. Yield: 64%. 1H-NMR (400 MHz, CDCl3) δ : 1.40 (t, J = 7.0 Hz, 3H), 3.73 (s, 6H), 3.88 (s, 3H), 4.03 
(q, J = 7.0 Hz, 2H), 6.43 (s, 2H), 6.77 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 1.2 Hz, 1H), 7.20 (d, J = 1.2 Hz, 1H), 7.33 
(d, J = 8.8 Hz, 2H). 13C-NMR (100 MHz, CDCl3) δ : 14.83, 56.35 (2C), 61.14, 63.52, 103.68 (2C), 114.21 (2C), 
122.46, 122.85, 128.75, 129.89 (2C), 134.46, 137.80, 146.82, 153.63 (2C), 159.15. MS (ESI): [M + 1]+ = 355.2. 
Anal. (C20H22N2O4) C, H, N.
2-(3′-Ethoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4l). Following general procedure A, the 
crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4l as a white solid, mp 
121–122 °C. Yield: 73%. 1H-NMR (400 MHz, CDCl3) δ : 1.42 (t, J = 7.2 Hz, 3H), 3.75 (s, 6H), 3.89 (s, 3H), 4.12 (q, 
J = 7.2 Hz, 2H), 6.44 (s, 2H), 6.76 (dd, J = 8.4 and 1.2 Hz, 1H), 6.91 (dt, J = 8.2 and 1.4 Hz, 1H), 7.05 (d, J = 1.2 Hz, 
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1H), 7.11 (m, 1H), 7.15 (d, J = 1.2 Hz, 1H), 7.23 (d, J = 1.2 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ : 15.36, 56.37 
(2C), 60.48, 63.12, 103.69 (2C), 113.79 (2C), 115.83, 120.85, 122.95, 128.96, 129.23, 131.51, 134.34, 146.68, 153.65 
(2C), 158.76. MS (ESI): [M + 1]+ = 355.1. Anal. (C20H22N2O4) C, H, N.
2-(2′-Ethoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4m). Following general procedure A, the 
crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4m as a white solid, mp 
130-132 °C. Yield: 64%. 1H-NMR (400 MHz, CDCl3) δ : 1.00 (t, J = 7.2 Hz, 3H), 3.63 (s, 6H), 3.64 (q, J = 7.2 Hz, 
2H), 3.79 (s, 3H), 6.32 (s, 2H), 6.71 (d, J = 8.4 Hz, 1H), 6.99 (dt, J = 7.6 and 0.8 Hz, 1H), 7.23 (d, J = 1.2 Hz, 1H), 
7.26 (d, J = 1.2 Hz, 1H), 7.31 (dt, J = 8.4 and 1.6 Hz, 1H), 7.5 (dd, J = 7.6 and 2.0 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3) δ : 14.44, 56.03 (2C), 61.01, 63.24, 101.26 (2C), 111.44 (2C), 120.62, 120.70, 129.07, 130.70, 132.14, 134.84, 
136.73, 145.00, 153.09 (2C), 156.45. MS (ESI): [M + 1]+ = 355.3. Anal. (C20H22N2O4) C, H, N.
2-(3′-Fluoro-4′-ethoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4n). Following general procedure A, 
the crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4n as a cream colored 
solid, mp 127–129 °C. Yield 58%. 1H-NMR (400 MHz, CDCl3) δ : 1.46 (t, J = 6.8 Hz, 3H), 3.82 (s, 6H), 3.94 (s, 
3H), 4.12 (q, J = 6.8 Hz, 2H), 6.54 (s, 2H), 7.07 (m, 2H), 7.36 (dd, J = 7.8 and 2.2 Hz, 1H), 7.82 (m, 2H). 13C-NMR 
(100 MHz, CDCl3) δ : 14.60, 56.90 (2C), 61.30, 65.13, 103.78 (2C), 105.36, 113.61, 114.79, 116.27, 120.24, 123.58, 
127.50, 130.39, 140.03, 150.51, 152.98 (2C), 154.51. MS (ESI): [M + 1]+ = 373.4. Anal. (C20H21FlN2O4) C, H, N.
2-(3′-Chloro-4′-ethoxyphenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4o). Following general procedure 
A, the crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4o as a white solid, 
mp 140–142 °C. Yield: 67%. 1H-NMR (400 MHz, CDCl3) δ : 1.45 (t, J = 7.2 Hz, 3H), 3.75 (s, 6H), 3.88 (s, 3H), 4.07 
(q, J = 7.2 Hz, 2H), 6.44 (s, 2H), 6.76 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 1.2 Hz, 1H), 7.18 (dd, J = 8.4 and 2.2 Hz, 1H), 
7.20 (d, J = 1.2 Hz, 1H), 7.57 (d, J = 2.2 Hz, 1H). 13C-NMR (100 MHz, CDCl3) δ : 14.69, 56.43 (2C), 61.19, 64.77, 
103.72 (2C), 112.50, 122.62, 122.89, 123.57, 127.69, 128.93, 130.37, 134.11, 138.06, 145.42, 153.73 (2C), 154.54. 
MS (ESI): [M + 1]+ = 389.0. Anal. (C20H21ClN2O4) C, H, N.
2-(4′-(Ethylthio)phenyl)-1-(3′,4′,5′-trimethoxyphenyl)-1H-imidazole (4p). Following general procedure A, the 
crude residue was purified by flash chromatography, using EtOAc-petroleum ether 8-2 as eluent, to furnish 4p 
as a white solid, mp 143–145 °C. Yield: 72%. 1H-NMR (400 MHz, CDCl3) δ : 1.29 (t, J = 7.4 Hz, 3H), 2.92 (q, 
J = 7.4 Hz, 2H), 3.73 (s, 6H), 3.88 (s, 3H), 6.43 (s, 2H), 7.13 (d, J = 1.2 Hz, 1H), 7.17 (d, J = 8.6 Hz, 2H), 7.22 (d, 
J = 1.2 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H). 13C-NMR (100 MHz, CDCl3) δ : 14.23, 27.08, 56.35 (2C), 61.17, 63.52, 
103.62 (2C), 122.97, 127.54, 127.88 (2C), 128.74 (2C), 129.05, 134.27, 137.60, 146.33, 153.70 (2C). MS (ESI): 
[M + 1]+ = 371.2. Anal. (C20H22N2O3S) C, H, N.
1-(3′,4′,5′-Trimethoxyphenyl)-2-(4′-n-propoxyphenyl)-1H-imidazole (4q). Following general procedure A, the 
crude residue was purified by flash chromatography, using EtOAc as eluent, to furnish 4q as a yellow oil. Yield: 
69%. 1H-NMR (400 MHz, CDCl3) δ : 1.01 (t, J = 7.4 Hz, 3H), 1.80 (m, 2H), 3.73 (s, 6H), 3.86 (s, 3H), 3.89 (q, 
J = 7.4 Hz, 2H), 6.43 (s, 2H), 6.76 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 1.2 Hz, 1H), 7.29 (d, J = 1.2 Hz, 1H), 7.36 (d, 
J = 8.8 Hz, 2H). 13C-NMR (100 MHz, CDCl3) δ : 10.54, 22.59, 56.33 (2C), 61.14, 69.56, 103.63 (2C), 114.21 (2C), 
122.46, 122.74, 128.71, 129.85 (2C), 134.46, 137.73, 146.82, 153.61 (2C), 159.32. MS (ESI): [M + 1]+ = 369.2. 
Anal. (C21H24N2O4) C, H, N.
Molecular Modeling.  All molecular modeling studies were performed on a MacPro dual 2.66 GHz Xeon 
running Ubuntu 14.04. The tubulin structure was downloaded from the PDB data bank (http://www.rcsb.org/; 
PDB code 1SA0)42. Hydrogen atoms were added to the protein, using the Protonate 3D routine of the Molecular 
Operating Environment (MOE)43. Ligand structures were built with MOE and minimized using the MMFF94x 
force field until a RMSD gradient of 0.05 kcal mol− 1 Å− 1 was reached. The docking simulations were performed 
using PLANTS applying the following parameters: search algorithm: aco_ants 20, aco_evap 0.15, aco_sigma 2.0; 
binding site: bindingsite_center [116.763 90.640 6.248], bindingsite_radius 12; cluster algorithm: cluster_rmsd 
2.0, cluster_strucures 30; scoring function: chemplp44.
Molecular dynamics were performed using the Desmond package for MD simulation45: OPLS-AA force 
field in explicit solvent, employing the TIP3 water model was used. The initial coordinates for MD simulation 
were taken from the best docking experiment results for each single ligand. A cubic water box was used for 
the solvation of the system, ensuring a buffer distance of approximately 11 Å between each box side and the 
complex atoms. The system was neutralized adding 30 sodium counter ions. The systems were minimized and 
pre-equilibrated using the default relaxation routine implemented in Desmond. A 10 ns MD simulation was per-
formed, during which the equation of motion were integrated using a 2 fs time step in the NPT ensemble, with 
temperature (300 K) and pressure (1 atm) constant. All other parameters were set using the Desmond default 
values. Data were collected every 4 ps (energy) and every 16 ps (trajectory). Visualization of protein-ligand com-
plexes and MD trajectory analysis were carried out using Maestro, and the RMSD analyses were performed using 
the Simulation Event Analysis tool of Desmond. Protein-ligand frames, for each compound simulation, were 
extracted every 0.3 ns (total of 24 frames for each single ligand) from the last 7 ns of simulation. For each frame, 
the ligand and the protein were separated and their Δ Gbinding was calculated using the MM/GBSA method as 
implemented in the Prime module from Maestro using the default settings. Finally, the average of the computed 
Δ Gbinding for the 24 frames were plotted against the experimental data (Fig. S2).
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Biological assays
Materials and Methods.  Cell growth conditions and antiproliferative assay. Human T-cell leukemia 
(CCRF-CEM and Jurkat) and human B-cell leukemia (SEM) cells were grown in RPMI-1640 medium (Gibco, 
Milano, Italy). Breast adenocarcinoma (MCF7), human cervix carcinoma (HeLa), and human colon adenocar-
cinoma (HT-29) cells were grown in DMEM medium (Gibco, Milano, Italy), all supplemented with 115 units/
mL penicillin G (Gibco, Milano, Italy), 115 μg/mL streptomycin (Invitrogen, Milano, Italy), and 10% fetal bovine 
serum (Invitrogen, Milano, Italy). Stock solutions (10 mM) of the different compounds were obtained by dissolv-
ing them in dimethyl sulfoxide (DMSO). Individual wells of a 96-well tissue culture microtiter plate were inocu-
lated with 100 μ L of complete medium containing 8 × 103 cells. The plates were incubated at 37 °C in a humidified 
5% CO2 incubator for 18 h prior to the experiments. After medium removal, 100 μ L of fresh medium containing 
the test compound at different concentrations was added to each well in triplicate and incubated at 37 °C for 72 h. 
The percentage of DMSO in the medium never exceeded 0.25%. This was also the maximum DMSO concentra-
tion in all cell-based assays described below. Cell viability was assayed by the (3-(4,5-dimethylthiazol-2-yl)-2,5-d
iphenyltetrazolium bromide test as previously described21. The IC50 was defined as the compound concentration 
required to inhibit cell proliferation by 50%, in comparison with cells treated with the maximum amount of 
DMSO (0.25%) and considered as 100% viability. PBL from healthy donors were obtained by separation on a 
Lymphoprep (Fresenius KABI Norge AS) gradient. After extensive washing, cells were resuspended (1.0 × 106 
cells/mL) in RPMI-1640 with 10% fetal bovine serum and incubated overnight. For cytotoxicity evaluations in 
proliferating PBL cultures, non-adherent cells were resuspended at 5 × 105 cells/mL in growth medium, contain-
ing 2.5 μg/mL PHA (Irvine Scientific). Different concentrations of the test compounds were added, and viability 
was determined 72 h later by the MTT test. For cytotoxicity evaluations in resting PBL cultures, non-adherent 
cells were resuspended (5 × 105 cells/mL) and treated for 72 h with the test compounds, as described above.
Effects on tubulin polymerization and on colchicine binding to tubulin.  To evaluate the effect of the 
compounds on tubulin assembly in vitro22, varying concentrations of compounds were preincubated with 10 μ M 
bovine brain tubulin in glutamate buffer at 30 °C and then cooled to 0 °C. After addition of 0.4 mM GTP (final 
concentration), the mixtures were transferred to 0 °C cuvettes in a recording spectrophotometer equipped with 
an electronic temperature controller and warmed to 30 °C. Tubulin assembly was followed turbidimetrically at 
350 nm. The IC50 was defined as the compound concentration that inhibited the extent of assembly by 50% after 
a 20 min incubation. The ability of the test compounds to inhibit colchicine binding to tubulin was measured as 
described22, except that the reaction mixtures contained 1 μ M tubulin, 5 μ M [3H]colchicine and 1 or 5 μ M test 
compound.
Flow Cytometric Analysis of Cell Cycle Distribution.  5 × 105 HeLa or Jurkat cells were treated with 
different concentrations of the test compounds for 24 h. After the incubation period, the cells were collected, 
centrifuged, and fixed with ice-cold ethanol (70%). The cells were then treated with lysis buffer containing RNase 
A and 0.1% Triton X-100 and then stained with PI. Samples were analyzed on a Cytomic FC500 flow cytometer 
(Beckman Coulter). DNA histograms were analyzed using MultiCycle for Windows (Phoenix Flow Systems).
Apoptosis Assay.  Cell death was determined by flow cytometry of cells double stained with annexin V/FITC 
and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure the surface exposure of phosphati-
dyl serine on apoptotic cells according to the manufacturer’s instructions (Annexin-V Fluos, Roche Diagnostics).
Western Blot Analysis.  HeLa cells were incubated in the presence of 4o and, after different times, were 
collected, centrifuged, and washed two times with ice cold phosphate buffered saline (PBS). The pellet was then 
resuspended in lysis buffer. After the cells were lysed on ice for 30 min, lysates were centrifuged at 15000 × g at 
4 °C for 10 min. The protein concentration in the supernatant was determined using the BCA protein assay rea-
gents (Pierce, Italy). Equal amounts of protein (10 μ g) were resolved using sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) (Criterion Precast, BioRad, Italy) and transferred to a PVDF Hybond-P mem-
brane (GE Healthcare). Membranes were blocked with a bovine serum albumin solution (5% in Tween PBS 1X), 
the membranes being gently rotated overnight at 4 °C. Membranes were then incubated with primary antibodies 
against Bcl-2, PARP, cdc25c, CDC20, ROCK1, MAD2, p-H2AXSer139, cyclin B, p-cdc2Tyr15, p-PLK1Tyr210 (all from 
Cell Signaling), caspase-3 (Alexis), or β -actin (Sigma-Aldrich) for 2 h at room temperature. Membranes were next 
incubated with peroxidase labeled secondary antibodies for 60 min. All membranes were visualized using ECL 
Select (GE Healthcare), and images were acquired using an Uvitec-Alliance imaging system (Uvitec, Cambridge, 
UK). To ensure equal protein loading, each membrane was stripped and reprobed with anti-β -actin antibody.
In vivo animal studies.  Animal experiments were approved by our local animal ethics committee (OPBA, 
Organismo Preposto al Benessere degli Animali, Università degli Studi di Brescia, Italy) and were executed in 
accordance with national guidelines and regulations. Procedures involving animals and their care conformed 
with institutional guidelines that comply with national and international laws and policies (EEC Council 
Directive 86/609, OJ L 358, 12 December 1987) and with “ARRIVE” guidelines (Animals in Research Reporting 
In Vivo Experiments).
Six week old C57BL/6 mice (Charles River, Calco) were injected subcutaneously into the dorsolateral flank 
with 2.5 × 105 BL6-B16 murine melanoma cells in 200 μ L-total volume of PBS. When tumors were palpable, ani-
mals were treated intraperitoneally every other day with different doses of test compounds dissolved in 50 μ L of 
DMSO. Tumors were measured in two dimensions, and tumor volume was calculated according to the formula 
V = (D × d2)/2, where D and d are the major and minor perpendicular tumor diameters, respectively.
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Statistical analysis.  Unless indicated differently, the results are presented as mean ± SEM. The differences 
between different treatments were analyzed, using the two-sided Student’s t test. P values lower than 0.05 were 
considered significant.
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